Kaiser Permanente Statement on Verdict in Neurontin Case

Kaiser Permanente Statement on Verdict in Neurontin Case

We are very pleased that justice has been achieved for our members and the physicians, pharmacists and staff who care for them.

Kaiser Permanente, along with the rest of the medical world, relied on the published science about Neurontin's effectiveness, not knowing it had been wrongfully manipulated. As a result, we ultimately spent more than one hundred million dollars on a very expensive drug that we now know is no more effective than a placebo for pain, bipolar, and many other conditions it was promoted to relieve.

This jury's decision is a victory for evidence-based medicine. We hope this decision will send a message to the medical community and pharmaceutical industry that manufacturers must adhere to high ethical and legal standards in their research and marketing of drugs.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.